• Applications
•  ›Patient Selection
•  ›Adverse Effects
•  ›Target Identification
•  ›Drug Repositioning
•  ›Early Detection

Applications

The monitoring of serum autoantibodies in patients is an important tool for addressing many needs, from drug development to clinical trials. Different study designs enable the development of biomarker panels for addressing the following applications:

Patient Selection
A panel of biomarkers that reveals a patient’s likelihood to positive drug response prior to and during clinical trials provides great benefits to the patient and pharmaceutical companies alike... More

Predicting Adverse Drug Effects
Adverse immune reactions are an emerging and high profile hazard in the development of novel drugs. Whether a catastrophic systemic hyper-immune reaction, or liver damage such as hepatic autoimmune disease... More

Target Identification & Drug Development
The detection of disease-specific antibodies can lead to exciting new drug opportunities. For example, the discovery of cancer/testis antigen MAGEA3 has resulted in two major pharmaceutical companies... More

Drug Repositioning

Using the Patient Selection approach discussed above, pharmaceutical companies are now able to revitalize stalled drug programs. Some drugs encounter regulatory hurdles that could be overcome... More

Early Detection

Antibodies are well suited to non-invasive diagnostic applications. Since they are produced in abundance relative to diseased tissue, they give earlier warning of disease than other biomarker classes which can take time to accumulate to detectable levels... More

For more information on using this technology, click here.